Cambridge: Vesalius Therapeutics, a company pioneering a revolutionary platform to deliver breakthrough treatments for common ...

AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...

Cambridge, USA-based Vesalius Therapeutics has entered into a multi-target strategic alliance with the UK’s GSK to discover ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

Vesalius Therapeutics, a company pioneering a revolutionary platform to deliver breakthrough treatments for common diseases, today announced a multi-target strategic alliance with GSK to discover and ...

GSK has licensed a small molecule for Parkinson's and is teaming up on additional targets for the disease and another ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

Here are today's five things you need to know, including a Ground Round comeback, employer confidence and JFK auction items you can own.